NEW YORK (GenomeWeb News) — Cisbio Bioassays will offer BioTrove's mass spectrometry screening service for assay development and drug screening to customers in the US, BioTrove said today.
Under the co-exclusive distribution agreement, Cisbio will offer BioTrove's RapidFire high-throughput service as a label-free detection method in conjunction with its Homogenous Time-Resolved Fluorescence, or HTRF technology and services. BioTrove will perform the RapidFire services at its screening facility.
HTRF is used for the detection of molecular interactions of proteins in vitro and is used for primary and secondary drug development screening.
Used together, the RapidFire and HTRF technologies will be used to study standard drug targets in the lead discovery phase and around 20 percent of drug targets that are difficult to study using fluorescent or radiolabel screening, BioTrove said.
"Cisbio's expertise in HTRF technology and significant sales presence among biopharma clients, combined with BioTrove's unique mass-spectrometry technology, will now provide customers access to a single, comprehensive source for drug discovery screening analysis," BioTrove President and CEO Al Luderer said in a statement.